Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP

Clin Nucl Med. 1998 Aug;23(8):501-4. doi: 10.1097/00003072-199808000-00001.

Abstract

A patient with disseminated osseous metastases due to breast cancer reported multifocal pain. Because of persisting pain after a first cycle of chemotherapy, 1,295 MBq Re-186 HEDP was administered intravenously. Excellent pain relief was observed. Subsequently, the patient received further combined chemotherapy and Re-186 HEDP therapy and remained pain free. Tc-99m MDP bone imaging showed a significant regression of osseous metastases. It may be speculated that the combination of Re-186 HEDP and chemotherapy results in significantly increased palliation of metastatic bone disease.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / secondary*
  • Bone Neoplasms / therapy*
  • Breast Neoplasms / pathology*
  • Carcinoma, Ductal, Breast / secondary
  • Carcinoma, Ductal, Breast / therapy
  • Combined Modality Therapy
  • Etidronic Acid / therapeutic use*
  • Female
  • Humans
  • Middle Aged
  • Palliative Care / methods*
  • Radioisotopes / therapeutic use*
  • Radionuclide Imaging
  • Radiopharmaceuticals / therapeutic use
  • Rhenium / therapeutic use*
  • Technetium Tc 99m Medronate

Substances

  • Radioisotopes
  • Radiopharmaceuticals
  • Rhenium
  • Etidronic Acid
  • Technetium Tc 99m Medronate